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Introduction
Nuclear mRNA transport is often thought of in terms of trans-
location through the nuclear pore, but mRNA export also requires 
intranuclear progression of transcripts from the gene to the nuclear 
pore. In some genetic diseases, failed export of a mutant mRNA 
is critical to the phenotype, yet typically it is not well under-
stood how nuclear export is impeded or whether mutant mRNA 
accumulates at a specifi  c point within the nuclear structure. In 
fact, the examination of mRNA blocked at a specifi  c step in export 
may help illuminate the path whereby mRNA normally transits 
from the gene to the nuclear pore. The analysis of human disease 
gene mutations that impact nuclear metabolism of the mRNA 
provides an avenue to study both disease pathogenesis and the 
interrelationship between nuclear structure and steps in mRNA 
biogenesis. In addition, the study of naturally occurring disease 
alleles in patient cells provides the advantage that the mutant mRNA 
is expressed in a normal structural and physiological context.
This study examines the intranuclear fate of normal and 
triplet repeat–expanded transcripts in myotonic dystrophy type 1 
(DM1) to defi  ne the point in the nuclear structure where the 
progression of normal and mutant transcripts diverge, which, 
in turn, provides insight into the step at which mutant mRNA 
transport is blocked. In DM1, expansion of a CTG triplet repeat 
occurs in the 3′ untranslated region of the gene encoding dys-
trophia myotonica protein kinase (DMPK), a serine/threonine 
protein kinase (Aslanidis et al., 1992; Brook et al., 1992; Fu et al., 
1992; Mahadevan et al., 1992). Normal alleles have 5–35 repeats, 
whereas DM1 alleles have 50 to >1,000. It has been shown that 
the mutant DMPK genes encode mRNAs containing expanded 
repeat sequences and that these RNAs are sequestered in the 
nucleus, where they accumulate in discrete nuclear foci (Taneja 
et al., 1995; Hamshere et al., 1997; Liquori et al., 2001). However, 
it is not known whether normal DMPK mRNA associates with 
any defi  ned intranuclear nuclear structure after its transcription 
and whether this differs for the mutant RNA.
In addition to the defect in mRNA transport in DM1, it is 
hypothesized that the expanded repeat RNAs alter the nuclear 
distri  bution or activity of specifi  c CUG-binding proteins, which, 
in turn, affects the alternative splicing of other pre-mRNAs (Day 
and Ranum, 2005; Osborne and Thornton, 2006). Multiple pro-
teins such as CUG-binding protein (Timchenko et al., 1996, 2001; 
Philips et al., 1998), heterogeneous nuclear RNP H (hnRNP H; 
Kim et al., 2005), double-stranded RNA–binding proteins 
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  I
n myotonic dystrophy type 1 (DM1), triplet repeat 
expansion in the 3′ untranslated region of dystrophia 
myotonica protein kinase (DMPK) causes the nuclear 
retention of mutant messenger RNA (mRNA). Although 
the DMPK gene locus positions precisely at the outer edge 
of a factor-rich SC-35 domain, the normal mRNA consis-
tently accumulates within the domain, and this RNA is 
depleted upon transcriptional inhibition. In DM1, mutant 
transcripts detach from the gene but accumulate in gran-
ules that abut but do not enter SC-35 domains, suggesting 
that RNA entry into the domain is blocked. Despite their 
exclusion from these compartments, mutant transcripts are 
spliced. MBNL1 (muscleblind-like protein 1) is an alterna-
tive splicing factor that becomes highly concentrated with 
mutant RNA foci. Small interfering RNA–mediated knock-
down of MBNL1 promotes the accumulation or entry of 
newly synthesized mutant transcripts in the SC-35 domain. 
Collectively, these data suggest that an initial step in the 
intranuclear path of some mRNAs is passage from the 
gene into an SC-35 domain and implicate these structures 
in postsplicing steps before export.
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(Tian et al., 2000), or transcription factors Sp1 and retinoic acid re-
ceptor γ (Ebralidze et al., 2004) have been identifi  ed as inter  acting 
with CUG repeat RNA. MBNL1 (muscleblind-like protein 1), 
a known regulator of alternative splicing (Pascual et al., 2006), is 
an especially strong candidate. In DM1 cells, MBNL1 is seques-
tered in mutant DMPK RNA foci (Miller et al., 2000; Fardaei 
et al., 2001; Mankodi et al., 2001), and the loss of MBNL1 results 
in a phenotype that has similarities to DM1 (Kanadia et al., 2003).
Understanding how mutant DMPK RNA transport is 
blocked requires an appreciation of the relationship of the nor-
mal RNA to nuclear structure. The mammalian nucleus is com-
prised of several nonmembrane bound compartments, each 
containing specifi  c subsets of macromolecules. Of particular rel-
evance here, a host of pre-mRNA metabolic factors concentrate 
markedly in 10–30 irregularly bordered domains (Nyman et al., 
1986; Carter et al., 1991; Spector et al., 1991; Blencowe et al., 
1994; Hall et al., 2006), which are defi  ned here by staining for 
the spliceosome assembly factor SC-35 (Fu and Maniatis, 1990). 
These SC-35 domains (also known as speckles or splicing factor 
compartments) are also highly enriched in poly(A) RNA (Carter 
et al., 1991; Xing et al., 1993). SC-35 domains are associated 
with a specifi  c subset of active genes (Jolly et al., 1999; Smith 
et al., 1999; Moen et al., 2004), with many genes and gene-rich 
R-band DNA clustering around their periphery (Shopland et al., 
2003). Importantly, the genes position at the immediate edge of 
an SC-35 domain but not within them, whereas several pre-
mRNAs have been shown to detach from the gene and enter the 
domains (Xing et al., 1995; Smith et al., 1999), which contain 
multiple distinct mRNAs (Shopland et al., 2002).
Several observations suggest that the egress of specifi  c gene 
transcripts from a peripheral gene into the domain may be linked 
to postsplicing steps rather than just splicing itself. For COL1A1 
(collagen type 1 α1) RNA, it was shown that most introns are 
removed at the gene just outside the domain, which is consistent 
with most splicing being cotranscriptional (Johnson et al., 2000). 
Some genes lacking introns become associated with domains 
upon activation (Jolly et al., 1999). More recently, several factors 
linked to postsplicing complexes required for mRNA export have 
also been shown to be concentrated within these domains (Zhou 
et al., 2000; Masuda et al., 2005; Schmidt et al., 2006).
In osteogenesis imperfecta type I, a splicing defect in in-
tron 26 of the collagen 1 α1 gene results in an abnormal accu-
mulation of the mutant collagen RNA within SC-35 domains, 
indicating an impediment to the egress of the RNA from the 
domain (Johnson et al., 2000). This study suggested that SC-35 
domains are a screening point for properly processed mRNA, a 
concept supported by a study that described the movement of 
poly(A) RNA through SC-35 domains (Molenaar et al., 2004). 
We have proposed that nuclear export of some specifi  c mRNAs 
begins by passage through the SC-35 domain neighboring the 
gene. This process may consist of two distinct steps: entry of the 
newly formed mRNA into the domain and exit of export-ready 
mRNA from the domain. The study of osteogenesis imperfecta 
type I provides evidence for the second step, as it was shown 
that the exit of mutant mRNA from domains was blocked or 
impeded. However, it is not clear whether entry into the domain 
from the peripheral gene is also a discrete step.
In this study, we examine the status of normal and mutant 
DMPK RNA relative to intranuclear structure in both normal 
myoblasts and myoblasts from individuals with DM1. Although 
both normal and mutant transcripts detach from the gene, they 
show distinct distributions relative to SC-35 domains. Normal 
DMPK transcripts consistently accumulate within the SC-35 do-
main, emanating from a gene precisely positioned at the outer 
edge of the domain. In contrast, mutant transcripts detach from 
the gene but no longer progress within the SC-35 domain and 
accumulate in multiple round foci that accumulate at the outer 
boundary of SC-35 domains. We provide direct visual evidence 
that mutant DMPK RNA in foci is spliced despite its exclusion 
from the splicing factor–rich domains. We also examine the role 
of the MBNL1 protein in the sequestration of DMPK RNA car-
rying the repeat expansion and demonstrate that loss of MBNL1 
restores the ability of the mutant DMPK RNA to accumulate in 
domains. Our results suggest that egress of DMPK transcripts 
from the gene into an SC-35 domain is a normal step in the nu-
clear progression of this mRNA, and transcripts from the mutant 
allele are blocked from normal entry into SC-35 domains. This 
block correlates with the failed cytoplasmic export of mutant 
DMPK RNA, suggesting that export is not blocked at the nuclear 
pore but at a very early step in nucleoplasmic transport.
Results
DMPK mRNA accumulates within 
SC-35 domains
Although several active genes and their mRNAs associate 
closely with SC-35 domains, this association is locus specifi  c, as 
has been observed for slightly more than half of the 25 active 
endogenous genes studied (Hall et al., 2006). To determine 
whether the normal DMPK gene and its RNA associate with 
SC-35 domains, a sequential hybridization technique (Xing et al., 
1995; Johnson et al., 2000) was used to detect the DMPK mRNA 
in one color using a cDNA probe (2.3 kb) and the gene in a sec-
ond color using a cosmid probe ( 40 kb). As shown in Fig. 1 A, 
after hybridization to normal differentiated myotube nuclei, 
DMPK RNA is usually seen in two irregular tracklike accumula-
tions that are larger than and juxtaposed to the DMPK locus 
signal. RNA hybridization with the DMPK cDNA probe and 
costaining with an antibody to the spliceosome assembly factor 
SC-35 demonstrate that these RNA accumulations are found 
within SC-35 defi  ned domains (Fig. 1, C–J), with >84% (n = 
316) of signals examined (see Fig. 3) clearly overlapping part or 
most of the domain. 3D analysis (Fig. 1, K–P and Video 1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200706048/DC1) 
confi  rms that the DMPK RNA lies largely within the domain.
DNA hybridization of the DMPK gene locus also shows 
that 70–90% associate with an SC-35 domain (n = 136 signals; 
Fig. 1 B). We initially defi  ned association to indicate that two en-
tities appear to be in direct contact as viewed by light microscopy, 
with no visible separation (Xing et al., 1993). By this strict crite-
rion, 70% of DMPK loci associate with a domain, but an addi-
tional 20% show just a minute hairline separation (Fig. 1 B, left 
inset); thus, up to 90% of DMPK genes localize to the region of 
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the much lower theoretically and empirically derived random 
association rates; based on the volume occupied by SC-35 domains 
( 3–10%; Carter et al., 1993; Xing et al., 1993) and on associa-
tion frequencies of many nonassociated loci, the random associa-
tion frequencies are  5–25% (Xing et al., 1995; Smith et al., 
1999; Moen et al., 2004). Most importantly, although the loci are 
clearly associated with the domain edge, they are not within it like 
the RNA signal. Thus, although this may not represent all of the 
DMPK mRNA, an accumulation of DMPK transcripts emanates 
from one side of the gene, which is positioned at the domain 
boundary, into the SC-35 domain. Although DMPK is not as com-
plex and highly expressed, this structural arrangement is very 
Figure 1.  DMPK gene and RNA association with SC-35 
domains in normal muscle cells. (A) In normal myotube nuclei, 
the two DMPK gene loci (red) have larger, somewhat diffuse 
tracks of DMPK RNA (detected with a cDNA probe; green) 
juxtaposed to them. Although the two RNA tracks are not usu-
ally in contact with each other, this image shows the two 
tracks intermingling as they extend from the gene loci. The in-
set is a magniﬁ  cation of genes and RNA. (B) The majority of 
DMPK gene loci (red) are associated with the edge of SC-35–
deﬁ   ned domains (green) in myoblast nuclei. The inset is a 
magniﬁ  cation of genes and SC-35 domains. (C) 50MB-1 nor-
mal myotube nuclei showing an overlap of DMPK RNA (red; 
arrows) with SC-35 domains (green). (D and E) Magniﬁ  cation 
of domain showing that DMPK RNA enters but does not ﬁ  ll the 
domain. Magniﬁ  cation of domain (green; D) and SC-35 + 
RNA (E). Overlap appears yellow. (F–J) DMPK RNA tracks in 
normal HSMM myotube nuclei. (F) DMPK RNA signals alone. 
(G)  DMPK RNA signals (red) overlapping SC-35 speckles 
(green). Magniﬁ  cations of the DMPK RNA track (H), SC-35 
domain (I), and merged image (J) with RNA in red and SC-35 
in green show that the DMPK RNA diffuses throughout most 
of the domain. (K–P) Top (K–M) and side (N–P) views of 3D 
rendered image of DMPK RNA (red; K and N) and SC-35 
(green; M and P) shows that DMPK RNA is diffused through 
the SC-35 domain. Bars (A), 5 μm; (K) 1 μm.JCB • VOLUME 178 • NUMBER 6 • 2007  954
similar to that shown for mRNAs such as COL1A1 and myosin 
heavy chain, which were shown to represent posttranscriptional 
mRNA that has detached from the gene and accumulates within 
an adjacent SC-35 domain (Xing et al., 1995; Smith et al., 1999).
SC-35 domain–associated DMPK RNA foci 
are lost upon transcription inhibition
Although SC-35 domains are enriched for poly(A) RNA, much 
of this RNA remains in the domain long after transcription inhi-
bition (>6 h), leading to suggestions that poly(A) RNA in the 
domains is comprised of nuclear RNA that is not exported to the 
cytoplasm (see Discussion). Thus, because DMPK RNA is con-
sistently within splicing factor–rich domains, a question may 
remain as to whether this focus of RNA is trapped in the SC-35 
domain or whether it can be chased from domains after tran-
scription inhibition, as may be expected for an exported mRNA. 
To approach this question, we visualized DMPK RNA in normal 
myotube nuclei after transcription inhibition using dichloroben-
zimidazole ribofuranoside. Loss of discernible mRNA foci in 
myotube nuclei was scored (Fig. 2), and a half-life of these RNA 
accumulations was calculated to be  43 min. This half-life is 
similar to the export rate found for a fl  uorescently labeled ftz 
mRNA that also associated with nuclear speckles (Tokunaga 
et al., 2006) and is far shorter than the >15-h half-life reported 
for the expanded CUG repeat–containing DMPK RNA foci that 
are retained in the nucleus in DM1 cells (Davis et al., 1997).
The collective aforementioned results defi  ne the nuclear 
distribution of normal DMPK mRNA, in which recently synthe-
sized transcripts associate with a specifi  c nuclear compartment, 
laying a foundation for investigating any potential reorganization 
of the mutant mRNA. Our results demonstrate that accumulation 
within SC-35 domains is a normal part of the mRNA biogenesis 
and suggest that it is linked to the export of some (if not all) 
DMPK mRNA.
Mutant DMPK RNA accumulates in foci 
at the periphery of SC-35 domains
We next determined the relationship of nuclear-retained DMPK 
RNA containing triplet repeat expansion to SC-35 domains. 
A previous study briefl  y examined the relationship of mutant 
DMPK mRNA foci to SC-35 domains and concluded that there 
was no substantial association (Taneja et al., 1995). Hybridiza-
tion to DMPK mRNA in DM1 myoblasts from a homozygous 
DM1 patient (Fig. 3, A–C) shows that the mutant mRNA con-
taining expanded CUG repeats is typically seen within nuclei in 
numerous round, discrete spots, which we refer to as mutant 
RNA granules (MRGs) as opposed to the two more irregular 
tracks seen for the DMPK mRNA in normal muscle cell nuclei 
(Fig. 1 A). The numerous MRGs in DM1 myoblasts are not the 
result of several copies of the DMPK gene as confi  rmed by DNA 
hybridization (Fig. 3, G, I, and K). In DM1 nuclei, 92% of the 
numerous MRGs (on average more than four per nucleus in homo-
zygous muscle cells) associate with SC-35–defi  ned domains 
(Fig. 4). However, this association is markedly different than the 
RNA foci in normal muscle nuclei, which are reproducibly found 
within the SC-35 domain (Fig. 1, C–E). As quantifi  ed in Fig. 4, 
the bulk of the associations of MRGs with SC-35–defi  ned do-
mains shifts from internal (complete overlap) in normal muscle 
cells to an association with the edge of the domains in DM1. This 
edge association is apparent in most cases by simple 2D analy-
sis; in cases in which the DMPK RNA signal initially would be 
scored to overlap the SC-35, further 3D analysis found that it 
was most typically either in a hole of lower density SC-35 signal 
or actually above or below the SC-35 domain (Fig. 3, D and E). 
3D visualization of DM1 nuclei (Video 2, available at http://
www.jcb.org/cgi/content/full/jcb.200706048/DC1) supports 
the localization of these RNA foci predominantly at the outer 
edge of SC-35 domains.
It has previously been demonstrated that MRGs do not 
colo  calize with other nuclear structures, such as PML bodies, 
exosomes, and the perinucleolar compartment (Jiang et al.,   
2004). However, the presence of multiple MRGs in close associ-
ation with SC-35 domains suggested the possibility that the RNA 
could be in paraspeckles, which are novel nuclear domains that 
abut SC-35–defi  ned speckles (Fox et al., 2002). Simultaneous 
detection of the mutant RNA foci and the paraspeckle protein 
PSP1 clearly demonstrated that the signals were not overlapping 
(unpublished data).
Figure 2.  Loss of DMPK RNA foci after transcription inhibition. 
Detection of DMPK RNA accumulations was counted at differ-
ent time intervals after transcription inhibition with dichloro-
benzimidazole ribofuranoside (DRB) in normal differentiated 
muscle. 100 nuclei were scored at each time point. Red curve 
is the exponential least squares ﬁ  t through points using the 
equation y = 106.66e
−0.8771x. This equation allows the calcu-
lation of the half-life or time at which half as many RNA foci 
are present as 43.5 min. Error bars represent SD.DMPK MRNA IS BLOCKED AT SC-35 DOMAIN EDGE IN DM1 • SMITH ET AL. 955
We then combined simultaneous DNA, RNA, and SC-35 
detection in heterozygous DM1 myotube nuclei. As in normal 
muscle nuclei, DMPK genes in DM1 myoblasts show similar posi-
tioning at the edge of SC-35 domains. Thus, the change in DMPK 
RNA association is not caused by a shift in gene localization rela-
tive to SC-35 domains. Fig. 3 (F–I) shows that the two DMPK 
alleles are positioned at the edge of splicing factor domains. One 
allele has an irregular dispersed track of DMPK RNA extending 
from it into the adjacent domain, which is clearly characteristic of 
transcripts released from the normal allele into the SC-35 domains 
in normal muscle cells (Fig. 1, C–J). The other allele is distinct 
from the normal allele in that it has only a minute RNA signal 
  (nascent transcripts) that does not extend into the domain, similar 
to DMPK DNA and RNA signals seen in homozygous mutant 
DM1 nuclei (Fig. 3, J and K). This relationship of the DMPK 
genes, RNA, and SC-35 is apparent in 3D as seen in Video 3 (avail-
able at http://www.jcb.org/cgi/content/full/jcb.200706048/DC1).
In Fig. 3 (F–I), we also see that MRGs associate with 
domains other than the ones adjacent to the DNA loci. This sug-
gests that MRGs have drifted from the transcription site but 
clearly still show an affi  nity for the SC-35 domains. However, 
unlike the normal DMPK RNA, these MRGs are restricted to the 
periphery and do not enter the domains. This shift in localization 
relative to the SC-35 compartment in DM1 demonstrates that the 
normal path of DMPK RNA from the gene into the domain is 
blocked for RNA carrying the triplet repeat expansion. In con-
trast to mutant COL1A1 RNA in osteogenesis imperfecta type I, 
in which mutant transcripts entered the domain normally but 
failed to exit properly (Johnson et al., 2000), some block to ex-
port in DM1 occurs at the entry of the repeat-expanded tran-
scripts into the domain. Although we cannot exclude that some 
normal transcripts are exported without entering SC-35 domains, 
these results show that the block in export is correlated with a 
failure of mutant DMPK RNA entry into the domain.
Mutant DMPK transcripts within nuclear 
foci are spliced
The failure of the mutant DMPK RNA to enter SC-35 domains 
raises the question as to whether splicing occurs normally despite 
Figure 3.  Distribution of DMPK mRNA and SC-35 in DM1. (A) Myotube 
nuclei from a DM1 homozygote shows numerous DMPK RNA foci (red) abut-
ting but not overlapping SC-35 domains (green). (B and C) Magniﬁ  cations of 
domain (B) with DMPK mRNA (C) demonstrating the tight association of RNA 
foci with a domain, but only with the domain edge. (D and E) DMPK RNA foci 
are often in SC-35 holes. (D) DMPK RNA signal (red) in the DM1 myoblast sits 
in a region of decreased SC-35 staining (green). Signal intensities along the 
line in the image are shown in the linescan graph (E). (F and H) Three color 
images of DM1 heterozygote myotube nuclei. DMPK genes (red) are associ-
ated with the edge of SC-35 domains (visualized with an antibody to SRm300; 
blue). DMPK RNA hybridization (green) shows the RNA track emanating 
from one allele into the adjacent domain, whereas the other allele (presum-
ably the mutant) has very little RNA associated with it, but there are RNA foci 
that are associated with the neighboring domain. (G) Magniﬁ   cation of F 
to show detail. (I) Magniﬁ  cation of H to show detail. (J and K) DMPK RNA 
foci in the homozygous DM1 myoblast nucleus. Most RNA signals are 
in brighter foci (J and green signals in K), but small RNA signals are seen 
(J; arrows) that are associated with DMPK gene signals (K; red), likely repre-
senting nascent transcripts.
Figure 4.  Graph indicating the frequency of RNA distributions seen in 
normal (50MB-1) myotube nuclei and myotube nuclei derived from muscle 
of a DM1 homozygote. Myotube nuclei, n = 316; nuclei derived from mus-
cle of a DM1 homozygote, n = 209.JCB • VOLUME 178 • NUMBER 6 • 2007  956
the repeat expansion in the 3′ untranslated region, which pre-
vents their accumulations within these splicing factor–rich struc-
tures. Using Northern analysis of extracted cellular mRNA, 
an earlier study (Davis et al., 1997) was unable to detect intronic 
sequences in DMPK RNA derived from DM1 or normal cells, 
suggesting that splicing was unaffected. We directly addressed 
whether the mutant RNA foci still contain introns by visualizing 
RNA in intact DM1 cells using a PCR-generated probe encom-
passing the DMPK intron 9 simultaneously detected with a 
cDNA probe. In normal muscle nuclei that have just two high 
concentration sites of largely unspliced pre-mRNA emanating 
from each normal allele, intron 9 signals intermingle with much 
of the localized DMPK cDNA signal (Fig. 5 A). In contrast, the 
numerous bright foci of mutant DMPK RNA in DM1 cells (visu-
alized by their enrichment of MBNL1 protein; Fig. 6 A) lack the 
intron 9 signal (Fig. 5 B). Similar results are seen when using a 
DMPK cDNA probe to detect RNA foci (unpublished data). This 
result illustrates that the mutant RNA in the MRGs of DM1 cells 
is spliced. Thus, although blocked entry into the SC-35 domain 
could still relate to failed export of the mRNA, it does not appear 
to affect splicing. This is consistent with other evidence that 
collagen pre-mRNA splicing occurs primarily at the edge of the 
SC-35 domain, whereas more mature mRNA is within the domain 
(Johnson et al., 2000).
Repeat transcripts in DM1 form structural 
accumulations with MBNL1
Evidence indicates that DM1 pathogenesis is caused, in large 
part, by a deleterious effect of the nuclear RNA accumulations, 
particularly on alternative splicing of specifi  c mRNAs. Seques-
tration of the alternative splicing factor MBNL1 has emerged as 
key to these splicing alterations (see Introduction).
In normal myotube nuclei, MBNL1 is seen in a broadly 
distributed, somewhat punctuate pattern by immunostaining (Fig. 
6 A). Interestingly, MBNL1 does not appear particularly concen-
trated in splicing factor–rich SC-35 domains but does show sites 
of punctuate concentration, some of which abut domains in nor-
mal cells. In DM1 muscle cells, the distribution of MBNL1 
changes markedly. As shown in Fig. 6 B, we fi  nd that the MBNL1 
nucleoplasmic signal is dramatically reduced in DM1 myotube 
nuclei and that MBNL1 is concentrated with mutant DMPK 
RNA in the very bright MRGs. These results corroborate evi-
dence from Jiang et al. (2004) and Lin et al. (2006) that MBNL1 
becomes sequestered with the repeat RNA accumulations co-
incident with MBNL1-dependent changes in alternative splicing 
patterns in muscle.
Myotonic dystrophy type 2 (DM2) has phenotypic similar-
ities to DM1 (Day et al., 2003), and, in DM2 cells, we also see 
that MBNL1 protein becomes sequestered with nuclear foci of 
mutant repeat RNA (unpublished data), which is consistent with 
the idea that overlapping clinical features in DM1 and DM2 may 
be caused by the common sequestration of MBNL1 (Day and 
Ranum, 2005). However, in DM2, the repeat expansion is in a 
quadruplet repeat (CCTG) in the fi  rst intron of a zinc fi  nger pro-
tein, znf9, on chromosome 3 ( Liquori et al., 2001). Although 
DM2 cells contain repeat RNA foci, unlike DM1, the foci con-
tain only intron sequences, and the intronic DM2 repeat does not 
impede znf9 mRNA export or translation (Botta et al., 2006; 
Margolis et al., 2006). Thus, because the repeat RNA foci in 
DM2 do not contain mRNA blocked from export, their relation-
ship to SC-35 domains was of less interest. We did note that 
there was some association of the MBNL1/Znf9 intronic RNA 
foci around SC-35 domains, although to a much lesser extent 
(51%; n = 604; unpublished data) than the DM1 MRGs (92%). 
Figure 5.  RNA foci in DM1 contain spliced DMPK RNA. 
(A) In HSMM myoblast nuclei, DMPK intron 9, which was de-
tected with a PCR-generated probe (green),detects an RNA 
focus that overlaps the focus of RNA detected with the DMPK 
cDNA probe (red). The right panel shows the three-color 
merged image. (B) In DM1 differentiated muscle cells, signals 
seen with the DMPK intron 9 probe (green) do not overlap 
DM1 RNA foci detected with MBNL1 (red). MBNL1 overlap 
with DMPK RNA is seen in Fig. 6 B. The right panel is a 
merged three-color image. Bar, 5 μm.DMPK MRNA IS BLOCKED AT SC-35 DOMAIN EDGE IN DM1 • SMITH ET AL. 957
Whether the aggregation with MBNL1 is partially responsible 
for the collection of MRGs around SC-35 domains is not known, 
but the important point is that MBNL1 sequestration is common 
to both DM1 and DM2, whereas blocked export of the mutant 
mRNA only occurs in DM1, possibly contributing to the unique 
clinical features of DM1.
MBNL1 down-regulation alters repeat 
RNA localization
Recent publications have suggested that MBNL1 and hnRNP H 
actually have roles in the formation of repeat RNA foci and 
RNA sequestration in DM1. Dansithong et al. (2005) have dem-
onstrated that reduction of MBNL1 levels by RNAi disrupts re-
peat RNA foci in proliferative DM1 myoblasts. Similarly, Kim 
et al. (2005) have found that siRNA-mediated knockdown of 
hnRNP H restores the export of repeat-containing RNA out of the 
nucleus. These two proteins interact, as MBNL1 is responsible for 
hnRNP H association with repeat foci (Paul et al., 2006). Thus, 
MBNL1 would appear to play a key role in the retention of mutant 
DMPK RNA in the nucleus by forming the MRG aggregates.
If the normal biogenesis and export of DMPK RNA are 
accomplished via SC-35 domains, these reports raise the possi-
bility that knockdown of MBNL1 might alter the localization 
of repeat-containing RNA relative to SC-35 domains so that it 
is within domains, as seen for the normal DMPK RNA. To ad-
dress this possibility, we performed siRNA-mediated knock-
down of MBNL1 in differentiated DM1 muscle cell cultures. 
To determine the effectiveness of the RNAi in individual cells, we 
performed RNA in situ hybridization on siRNA and control 
coverslips using CAG repeat oligonucleotides and stained for 
MBNL1. Coverslips were scored for differentiated nuclei that 
had repeat RNA foci with and without MBNL1 (Fig. 7, A and B). 
As seen in the graph in Fig. 7 C, 27% of differentiated muscle 
nuclei treated with siRNA (n = 148) had CUG repeat RNA foci 
(MRGs) without substantial levels of MBNL1, whereas CUG 
RNA colocalized with MBNL1 foci in all of the control nuclei 
(n = 142). This in situ approach demonstrates effective transfec-
tion and siRNA depletion of MBNL1 expression in a substantial 
subset of differentiated cells.
Although Dansithong et al. (2005) reported that MBNL1 
was necessary for mutant RNA focus integrity, we found intact 
RNA foci in cells in which MBNL1 expression was down-
regulated by RNAi 5 d after transfection. We believe there is a 
difference in results because our analysis was performed on 
nonproliferative cultures under low serum differentiation condi-
tions, whereas the cultures used by Dansithong et al. (2005) were 
dividing during the 5 d after transfection. We suggest that in their 
experiments, mutant DMPK RNA foci may have broken down 
during mitosis and not reformed afterward as a result of dilution 
and depletion of previously made MBNL1. Our evidence is in 
agreement with the statement by Dansithong et al. (2005) that 
the absence of MBNL1 is suffi  cient to prevent nucleation of the 
mutant RNA foci.
A triple label experiment in which CUG RNA, MBNL1, 
and SC-35 were detected was used to investigate changes in 
CUG RNA localization upon MBNL1 knockdown (Fig. 8 A). 
In nuclei in which MBNL1 expression was suppressed, we noted 
that there was commonly a single SC-35 domain that contained 
Figure 6.  MBNL1 is sequestered in mutant RNA foci in DM1. 
(A) In normal muscle, MBNL1 (red) is present in a diffuse nucleo-
plasmic pattern that neither enriched nor depleted in SC-35 
domains (green). (B) In DM1 muscle nuclei, DMPK RNA foci 
(green) overlap foci of MBNL1 (red). Bar, 5 μm.JCB • VOLUME 178 • NUMBER 6 • 2007  958
an irregular, rather diffuse accumulation of repeat RNA that was 
distinct from the round MRGs (Fig. 8 B; and see 3D visualiza-
tion in Video 4, available at http://www.jcb.org/cgi/content/full/
jcb.200706048/DC1). Based on scoring by two independent 
  investigators, these signals were far more common in the cells in 
which MBNL1 was knocked down (63% of nuclei; n = 39) than in 
control cells or in untransfected cells from the same experiment 
(8% of nuclei; n = 37; Fig. 8 C). These signals were reminiscent 
of diffuse DMPK RNA accumulations from the normal allele 
detected with a cDNA probe (Fig. 1, C–J; and Fig. 3, G and I). 
Thus, we suspected that these signals did not arise from the pre-
existing RNA/protein aggregates (MRGs) but are new repeat-
containing transcripts arising from the affected allele, which 
would not have any newly synthesized MBNL1 with which to 
complex as a result of the siRNA-mediated inhibition.
To address the possibility that the diffuse CUG RNA sig-
nals were new transcripts emanating from a DMPK gene locus, 
we performed another triple label experiment on MBNL1 knock-
down cells. In this experiment, we detected SC-35 followed by 
hybridization for CUG RNA with an oligonucleotide probe and a 
DNA hybridization with a DMPK genomic probe. Analysis of 
this experiment provided numerous clear examples of DMPK 
gene loci abutting more diffuse CUG RNA (mutant DMPK  RNA) 
signals within SC-35 domains (Fig. 9). In nuclei in which the dif-
fuse RNA signal and two DMPK gene loci were visible, the dis-
persed RNA signal was always adjacent to one of the genes. 
These results demonstrate that depletion of MBNL1 by RNAi al-
lows newly transcribed DMPK RNA containing expanded CUG 
repeats to enter the SC-35 domain abutting the gene locus.
Discussion
Findings presented here further our understanding of nuclear 
structure and mRNA transport and, at the same time, provide in-
sight into the cellular pathogenesis of DM1. We show that newly 
synthesized DMPK RNA accumulates within the interior of an 
SC-35–defi  ned domain in normal muscle nuclei, having ema-
nated from a gene positioned at the domain’s edge. In contrast, the 
mutant DMPK transcripts in DMI detach from the gene but are 
not within the domain; rather, they accumulate in multiple gran-
ules that gather at the edge of domains. This change in domain as-
sociation occurs in concert with mutant DMPK RNA retention in 
the nucleus. Although the transcripts do not appear to enter the 
SC-35 domain, they are nonetheless spliced. Down-regulation of 
MBNL1 changes the distribution of newly transcribed mutant 
DMPK RNA such that it is now found within the SC-35 domain.
Our studies examine the detailed relative distributions of 
gene/RNA/protein associated with normal versus mutant alleles 
but in static images that capture a window of time. A major ad-
vantage of this approach is that it provides information about 
the real endogenous gene and RNA, which are expressed in a 
native structural as well as physiological context. Although this 
does not provide direct visualization of molecules in live cells, 
our fi  ndings collectively provide evidence of the route occupied 
by at least a substantial fraction of these native transcripts. 
  Because transcripts clearly emanate from the gene, for the sake 
of this Discussion, we consider the gene point A and will con-
sider any accumulation of transcripts at a resolvable distance 
from the corresponding gene to have moved with respect to it.
Collectively, these fi  ndings suggest several important 
points regarding the relationship of the SC-35 domains to mRNA 
metabolism and transport. (1) The consistent positioning of both 
homologous DMPK genes at the outer edge of an SC-35 domain 
adds to the body of evidence that specifi  c active genes are orga-
nized relative to SC-35 domains, providing an example of an as-
sociated gene that is not particularly complex or highly expressed. 
(2) We interpret the accumulation of transcripts within the SC-35 
domain (to one side of the gene at the domain edge) to indicate a 
normal step in the path of DMPK mRNA for at least a substantial 
fraction of DMPK transcripts. The fact that mutant transcripts do 
not enter these domains further supports the idea that entry into 
the domains is a step that can be blocked by mutation. (3) Because 
MRGs contain spliced mRNA, passage into the splicing factor–
rich domain does not appear to be required for splicing, which 
is consistent with other evidence that most splicing occurs at 
the domain periphery (Johnson et al., 2000). These fi  ndings are 
Figure 7.  siRNA-mediated down-regulation of MBNL1. (A) Two nuclei in 
the same image frame showing the accumulation of MBNL (red) with CUG 
(DMPK) RNA (green). The left nucleus demonstrates the loss of MBNL1 rela-
tive to the nucleus on the right. (B) Linescan graphs of signal intensities 
along the lines drawn through each nucleus in A show the loss of MBNL1. 
(C) Quantitation of MBNL1 signal with CUG repeat foci in control (n = 142) 
and siRNA-treated (n = 148) nuclei. Bar, 10 μm.DMPK MRNA IS BLOCKED AT SC-35 DOMAIN EDGE IN DM1 • SMITH ET AL. 959
consistent with the idea that postsplicing steps linked to export 
may occur within the domain. (4) Blockage of mutant transcripts 
before entering SC-35 domains provides further evidence for 
the structural integrity of the SC-35 domain (with which normal 
and mutant alleles remain associated), which exists indepen-
dently of the presence of DMPK mRNA within it. Consistent 
with this, the normal DMPK mRNA does not occupy the whole 
domain of splicing factors, as might be expected if the domain 
was merely factors bound to this pre-mRNA. (5) Loss of DMPK 
RNA signals upon transcription inhibition demonstrates that the 
normal DMPK RNA accumulation in SC-35 domains does not 
represent RNA just trapped within the domain but is chased as 
would be expected for a transported mRNA. (6) Remarkably, of 
the two mutant pre- mRNAs studied thus far, both have shown 
abnormal accumulations at or within the SC-35 domains and not 
at other sites such as the nuclear envelope or nucleolus. Whereas 
mutant COL1A1 RNA in osteogenesis imperfecta accumulates 
to abnormal levels within the domain, mutant DMPK transcripts 
accumulate outside the domain. This supports a model in which 
passage into and release from these domains are distinct steps in 
the normal path of some pre-mRNAs.
Although we demonstrate that many DMPK transcripts are 
not randomly dispersed upon initial release from the gene, these 
results should not be misinterpreted as excluding the possibility 
that export of these mRNAs may also involve multidirectional 
diffusion, which is consistent with other models of RNA traffi  ck-
ing (Politz et al., 2003; Gorski et al., 2006). These collective fi  nd-
ings support a model of early steps in mRNA export and maturation 
as presented in Fig. 10.
This study provides evidence of a relationship between 
DMPK mRNA and SC-35–defi  ned speckles that is disrupted 
when a CUG expansion in DM1 prevents normal mRNA export. 
Despite numerous studies describing the association of specifi  c 
mRNAs with SC-35–defi  ned speckles (Xing et al., 1995; Jolly 
et al., 1999; Smith et al., 1999; Shopland et al., 2002), the idea 
that SC-35 domains contain mRNAs and/or play a role in mRNA 
export remains somewhat controversial (Hall et al., 2006). There-
fore, we will briefl  y address the two major pieces of evidence that 
Figure 8.  Down-regulation of MBNL1 changes CUG repeat 
RNA association with SC-35 domains. (A) Three-color image 
of myotube nucleus showing CUG repeat RNA (green) with-
out MBNL1 accumulation (red) in foci and in a diffuse pattern 
that overlaps an SC-35 domain (blue). (B) Several images of 
CUG repeat RNA (red) coincident with SC-35 domains (green) 
in different nuclei. Overlap appears yellow. (C) Frequency of 
CUG repeat RNA distributions relative to SC-35 domains. 
Bar, 5 μm.JCB • VOLUME 178 • NUMBER 6 • 2007  960
generate this uncertainty. First, the belief that SC-35 speckles do 
not contain appreciable short-lived pre-mRNAs is based on early 
fi  ndings that tritiated uridine incorporation labels the speckles 
(interchromatin granule clusters) very little relative to the sur-
rounding nucleoplasm (Fakan and Bernhard, 1971; Fakan, 1994; 
for review see Spector, 1993). However, a study did fi  nd newly 
synthesized BrUTP-labeled RNA concentrated within these do-
mains (Wei et al., 1999). Most importantly, labeling methods 
such as [
3H]uridine or bromo-UTP are wholly nonspecifi  c and do 
not necessarily refl  ect the distribution of pre-mRNA. These meth-
ods primarily label unknown heterogeneous nuclear RNA (Salditt-
Georgieff et al., 1981) and introns (most of pre-mRNA mass) that 
Figure 9.  Diffuse CUG RNA signals are associated with the 
DMPK gene locus. (A) Three-color image of SC-35 (blue) 
DMPK DNA (green) and CUG RNA (red) show two gene sig-
nals associated with SC-35 domains, but only one gene is 
juxtaposed to the diffuse CUG RNA signal overlapping SC-35. 
(B) Magniﬁ  cation of DMPK gene, CUG RNA, and SC-35 with 
the line representing the linescan in C. (D–F) Blue (D), red (E), 
and green (F) channels of the image in B. (G) Three-color 
image of SC-35 (blue) DMPK DNA (green) and CUG RNA 
(red) shows two gene signals associated with SC-35 domains, 
but only one gene is juxtaposed to the diffuse CUG RNA sig-
nal overlapping SC-35. (H) Magniﬁ  cation of the relevant re-
gion of nucleus in G. (I–K) Separated channels of the image 
in H. Bars, 5 μm.DMPK MRNA IS BLOCKED AT SC-35 DOMAIN EDGE IN DM1 • SMITH ET AL. 961
are rapidly removed and disperse during the labeling period (Xing 
et al., 1993; for review see Moen et al., 1995). Evidence in sup-
port of this concern has been strengthened in recent years by fi  nd-
ings that transcription of nongenic DNA is far more widespread 
throughout the genome than previously anticipated (Cheng et al., 
2005; Johnson et al., 2005). Furthermore, copious amounts of 
RNA throughout the nucleoplasm are detected by RNA hybrid-
ization using Cot-1 DNA, composed largely of repetitive ele-
ments such as Alu and long interspersed nuclear elements (Hall 
et al., 2002), which recent fi  ndings suggest is largely nongenic 
transcription (Hall et al., 2002; Chaumeil et al., 2006; Clemson 
et al., 2006). In short, uridine incorporation detects a great deal of 
RNA that is not mRNA and, as such, does not accurately repre-
sent the distribution of pre-mRNA in the nucleus.
Second, the demonstration that the poly(A) RNA signal 
often remains in SC-35 domains upon transcription inhibition 
(Lawrence et al., 1993; Huang et al., 1994) is often interpreted 
to indicate that this poly(A) RNA is not mRNA but a putative 
long-lived, polyadenylated, structural RNA. However, transcrip-
tional inhibition has complex effects on nuclear RNA distribu-
tions and transport that varies with the RNA. In a dramatic 
example of this, we recently identifi  ed an abundant noncoding 
polyadenylated nuclear RNA, NEAT1 (Hutchinson et al., 2007), 
that actually enters the SC-35 domains upon treatment with cer-
tain transcription inhibitors (unpublished data). This illustrates 
the diffi  culty of interpreting the nature of the poly(A) RNA in 
domains from transcription inhibition experiments. Our study 
demonstrates that at least some specifi  c mRNAs, such as DMPK 
RNA, do leave the SC-35 domain upon transcription inhibition. 
In addition, recent studies of labeled RNAs introduced into live 
cells indicate that poly(A) RNA (Molenaar et al., 2004) and spe-
cifi  c mRNAs (Tokunaga et al., 2006) passage through domains 
and that export-ready mRNA is present in speckles (Schmidt et al., 
2006). Thus, although our study takes a different approach to 
study naturally occurring mutations of an endogenous RNA, our 
fi  ndings complement and substantially extend approaches that 
seek to understand the behavior of endogenous molecules by 
examining labeled, microinjected RNAs in live cells.
In addition to its relevance for fundamental nuclear struc-
ture, this study contributes insight into the cellular pathogenesis 
of DM1. (1) We have identifi  ed a point in nuclear structure at 
which the paths of normal and mutant DMPK mRNA diverge. 
(2) As this difference correlates with cytoplasmic mRNA export, 
it defi  nes the intranuclear step at which the block in transport of 
many or all mutant DMPK transcripts likely occurs. (3) We pro-
vide evidence that the formation of MRGs mediated by MBNL1 
is responsible for blocking the mutant RNA from entry into the 
domain. Our analysis indicates that depletion of newly synthe-
sized MBNL1 allows newly transcribed DMPK RNA carrying 
CUG repeat expansions to accumulate within SC-35 domains in 
a manner similar to that seen with normal DMPK RNA. MBNL1 
may act in concert with other factors, such as hnRNP H, to bind 
Figure 10.  Model of SC-35 domain function. In this model, 
DMPK genes are positioned at the edge of SC-35 domains. 
The RNAs produced from these loci are primarily spliced at 
the edge of the domain. These mRNAs then transit into the 
domain (step 1). In the interior of the domain, the bound splic-
ing factors, such as small nuclear RNPs and serine-arginine 
proteins, are removed and recycle back to the domain edge. 
These are replaced by export factors such as tip-associated 
protein and Aly. The export-ready mRNAs then leave the do-
main (step 2) and are transported to the nuclear envelope. 
In DM1, the RNA is spliced, but expanded repeat sequences 
in the RNA are bound by MBNL1 (and perhaps other factors), 
forming aggregates (MRGs) that do not enter the domain and 
impeding export of the RNA.JCB • VOLUME 178 • NUMBER 6 • 2007  962
CUG repeat RNA and form the RNA/protein aggregates. Thus, 
both the nuclear retention of mutant DMPK RNA as well as se-
questration of specifi  c nuclear factors like MBNL1 and hnRNP H 
are likely involved in the complex DM1 phenotype.
Materials and methods
Cell culture
The normal muscle cultures used were human skeletal muscle myoblasts 
(HSMMs; Clonetics) and 50Mb. Myoblast strain 50Mb (normal myoblast 
preparations ﬂ  ow sorted to substantially remove contaminating ﬁ  broblasts) 
was provided by H. Blau (Stanford University, Palo Alto, CA; Webster 
et al., 1988). It was obtained from the vastus lateralis muscle of a 10-yr-old 
male with no known muscle pathologies. For propagation, cells were cul-
tured at subconﬂ  uent density in serum-rich medium with medium changes 
every other day. To induce muscle differentiation, cultures were grown to 
near conﬂ  uence and maintained in low serum medium without further me-
dium changes until the appearance of myotubes. Propagation medium was 
Ham’s F-10 supplemented with 20% FCS, 1% vol/vol chick embryo extract 
(60 Å ultraﬁ  ltrate; Invitrogen), 1 mM insulin, and 1 mM dexamethasone 
(Sigma-Aldrich), whereas differentiation medium contained DME low and 
2% horse serum. Both contained 200 U/ml penicillin and 200 mg/ml 
streptomycin. HSMMs were grown in SkGM BulletKit media (Cambrex) 
with an additional 1.5% FBS. The differentiation media was DME–F-12 
with 2% horse serum added when the cells reached  60% conﬂ  uence.
Homozygous DM1 myoblasts (DM(SW)) were derived from a se-
verely affected homozygote (provided by L. Timchenko, Baylor College of 
Medicine, Houston, TX; Caskey et al., 1996)). In our hands, this cell line 
ceased to differentiate after a few passages. Heterozygous DM1 myoblast 
cultures F1D and myoblast C were obtained from C. Thornton (Wellstone 
Muscular Dystrophy Cooperative Research Center, Rochester, NY). These 
myoblasts were grown in Ham’s F-10 with 0.12% NaHCO3, 15% FBS, 5% 
deﬁ  ned supplemental calf serum, and 2 mM L-glutamine and penicillin/
streptomycin. Fusion medium was described in the previous paragraph. 
DM2 ﬁ  broblasts were provided by L. Ranum (University of Minnesota, Minnea-
polis, MN). DM2 ﬁ  broblasts were grown in DME with 10% FBS, penicillin/
streptomycin, and L-glutamine.
Probes and antibodies
DMPK RNA was detected using a 2.3-kb DMPK cDNA clone pRMK 
(Timchenko et al., 1995). A genomic clone, cosmid F18894 (L08835) over-
lapping the DMPK gene, which was obtained from the Human Genome 
Center (Lawrence Livermore National Laboratory, Livermore, CA), was used 
for DNA detection. The 2-kb DMPK intron 9 probe was generated by PCR 
ampliﬁ  cation from the F18894 clone using primers G  A  G  T  T  G  C  A  G  G  A  T  C  A-
G  T  C  T  T  G  G  A   and T  G  C  T  G  A  T  T  C  T  C  T  G  G  T  G  G  A  G  A  A  C  . Znf9 gene and RNA 
detection were performed using PCR-generated probes encompassing ex-
ons 2–5 of the znf9 gene. Probes were generated by PCR ampliﬁ  cation of a 
bacterial artiﬁ  cial chromosome (Rp11-814L21; BACPAC Resource Center, 
Children’s Hospital Oakland Research Institute, Oakland, CA) using primers 
A  A  A  C  C  T  T  T  G  C  C  A  T  C  A  C  C  A  T  C   and G  C  C  T  T  G  C  A  A  A  T  T  G  T  C  T  G  G  A  T  . Biotin or 
ﬂ  uorescein end-labeled oligonucleotide probes (C  A  G  C  A  G  C  A  G  C  A  G  C  A  G-
C  A  G   and C  A  G  G  C  A  G  G  C  A  G  G  C  A  G  G  C  A  G  G  C  A  G  G  C  A  G  G  ) were used to 
detect DM1 (CUG) and DM2 (CCUG) repeat RNAs, respectively. All probes 
except direct-labeled oligonucleotides were labeled using nick translation 
as described previously (Johnson et al., 1991; Tam et al., 2002).
SC-35 domains were detected with an antibody to the spliceosome 
assembly factor SC-35 (Sigma-Aldrich; Fu and Maniatis, 1990) or to an 
antibody to the splicing coactivator SRm300 (provided by B. Blencowe, 
University of Toronto, Toronto, Canada; Blencowe et al., 1998). MBNL1 
was detected with monoclonal antibodies 3B10 and A2764, which were 
obtained from C. Thornton. An antibody to hnRNP H was obtained from 
D. Black (Howard Hughes Medical Institute/University of California, 
Los Angeles, Los Angeles, CA).
In situ hybridization
The methods used in this study, including procedures for nonisotopic probe 
preparation and FISH, have been published in detail previously (Johnson 
et al., 1991; Tam et al., 2002). Two-color detection of RNA and genes 
simultaneously was performed by sequential hybridization and detection of 
RNA followed by ﬁ  xation, NaOH treatment, and DNA hybridization (Xing 
et al., 1995). In some experiments, before or after hybridization, samples were 
stained with antibodies as described previously (Xing et al., 1993, 1995).
MBNL1 RNAi
RNAi was performed by methods adapted from Dansithong et al. (2005). 
Double-stranded siRNA to MBNL1 (5′-C  A  C  U  G  G  A  A  G  U  A  U  G  U  A  G  A  G  A-
dTdT-3′) was obtained from Dharmacon. Fresh cultures of myoblasts from DM1 
patients (myoblast C) were cultured and differentiated as described in the 
Cell culture section. 5-d differentiated myoblast cultures on coverslips in six-
well plates were rinsed twice with Opti-MEM (Invitrogen). For each coverslip, 
5 μl Oligofectamine (Invitrogen) and 375 pmol MBNL1 siRNA in a 1-ml total 
volume of Opti-MEM were preincubated for 20 min at room temperature 
and added to the cells. Controls had no siRNA. Transfection was incubated 
at 37°C overnight and replaced with differentiation media (DME + 5% 
horse serum). Cells were extracted and ﬁ  xed at 5 d after transfection.
Microscopy and analysis
Images presented in this study are either single plane or extended focus im-
ages from z stacks (step size = 100 nm) and were acquired using an Axio-
vert 200 microscope or an Axiophot microscope (Carl Zeiss MicroImaging, 
Inc.) equipped with a 100× NA 1.4 planApo objective using Axiovision 
(Carl Zeiss MicroImaging, Inc.) or MetaMorph (Universal Imaging Corp.) 
imaging software. The multiband pass dichroic and emission ﬁ  lter  sets 
(model 83000; Chroma Technology Corp.) were used with excitation ﬁ  lters 
set up in a wheel to prevent optical shift. Images were captured on an Orca-
ER camera (Hamamatsu) or a CCD camera (200 series; Photometrics). 
Z stacks were further processed using constrained iterative deconvolution 
in Axiovision 4.1 (Carl Zeiss MicroImaging, Inc.) and displayed as extended 
focus projections in some cases. Rendered images are maximum value 
projections. Results shown are from multiple experiments and were scored 
by several investigators.
Online supplemental material
Video 1 demonstrates the colocalization of normal DMPK RNA and an SC-35 
domain in 3D. Video 2 is a 3D representation showing that mutant DMPK 
RNA forms foci that are predominantly at the edge of SC-35 domains in 
DM1 muscle cell nuclei. Video 3 demonstrates in 3D that both DMPK gene 
loci associate with SC-35 domains in heterozygous DM1 muscle but only 
one locus has visible RNA accumulating in the adjacent domain. Video 4 
is a 3D representation showing that upon siRNA-mediated knockdown of 
MBNL1, CUG RNA (representing mutant DMPK RNA) localizes within an 
SC-35 domain adjacent to a DMPK gene locus. Online supplemental material 
is available at http://www.jcb.org/cgi/content/full/jcb.200706048/DC1.
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